Click Here to return To Results

 

Oral Fingolimod (FTY720) in Multiple Sclerosis: Two-Year Results of a Phase II Extension Study Neurol 72:73-79, OConnor,P.,et al, 2009 See this aricle in Pubmed Article Abstract Once-daily oral treatment with FTY720, 1.25 or 5.0 mg for up to 2 years, was well tolerated and was associated with low relapse rates and lesion activity.

Related Tags

(click to filter results - removes previous filter) efficacy fingolimod gadolinium immunomodulation MRI MRI,abnormal MRI,contrast enhanced multiple sclerosis multiple sclerosis,relapsing multiple sclerosis,treatment of safety treatment of neurologic disorder

Click Here to return To Results